VolitionRX (NYSEAMERICAN:VNRX) Trading 9% Higher - Should You Buy?

Key Points

• VolitionRX stock has surged by 9%, reaching a high of $0.74 during trading, up from a previous close of $0.62.
• Trading volume spiked to 991,634 shares, a significant increase of 367% from the average volume of 212,426 shares.
• VolitionRX specializes in developing blood tests for diagnosing and monitoring various cancers, sepsis, and COVID-19, with a market capitalization of $73.04 million.

VolitionRX Limited (NYSEAMERICAN:VNRX - ) traded up 9% on Tuesday . The company traded as high as $0.74 and last traded at $0.68. 991,634 shares traded hands during mid-day trading, an increase of 367% from the average session volume of 212,426 shares. The stock had previously closed at $0.62.

VolitionRX Trading Up 9.0%

The firm has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.60. The company has a market capitalization of $73.04 million, a PE ratio of -2.72 and a beta of 1.27.

VolitionRX Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.